Crossmark

European Headache Federation guideline on idiopathic intracranial hypertension

Crossref DOI link: https://doi.org/10.1186/s10194-018-0919-2

Published Online: 2018-10-08

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hoffmann, Jan https://orcid.org/0000-0002-2103-9081
Mollan, Susan P

Paemeleire, Koen

Lampl, Christian

Jensen, Rigmor H

Sinclair, Alexandra J
Funding

Funding for this research was provided by:

National Institute for Health Research (NIHR-CS-011-028)

Medical Research Council (MR/K015184/1)
License Information

Text and Data Mining valid from 2018-10-08
More Information

Article History

Received: 31 July 2018

Accepted: 14 September 2018

First Online: 8 October 2018

Ethics approval and consent to partcipate

: Not applicable.

: Not applicable.

: JH received honoraria for consulting for and/or serving on advisory boards for Allergan, Autonomic Technologies Inc. (ATI), Chordate Medical AB, Eli Lilly, Hormosan Pharma, Novartis and Teva. He received honoraria for speaking from Allergan, Autonomic Technologies Inc. (ATI), Chordate Medical AB, Novartis and Teva. These activities are/were unrelated to the submitted work. SPM reports no conflict of interest. KP reports no conflict of interest. CL reports no conflict of interest. RHJ has received honoraria for lectures and patient leaflets from MSD, Berlin-Chemie, Menarini, Autonomic Technologies Inc. (ATI) and Pfizer; participated in medical advisory boards for ATI and Electrocore and conducted clinical trials for ATI and Eli Lilly. AJS reports no conflict of interest.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.